



National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

December 2, 1991

J. W. Nowicky
Laimgrubengasse 19/7
A-1060 Vienna
Austria

Dear Dr. Nowicky:

In response to your letters of November 10 and 26, 1991, to Dr. Broder, I am enclosing the data you requested for doxorubicin (NSC 123127), daunomycin (NSC 82151), 5-fluorouracil (NSC 19893), and your material Ukrain (NSC 631570).

The information supplied is in the form of the standard supplier reporting package for the three most recent experiments on each of the standard agents and two for your material. The supplier report packages include: In Vitro Testing Results, Dose Response Curves, Mean Graphs, and the Dose Response Matrix.

The original review summary page of the supplier report package has been phased out, since it was felt to cause some confusion in interpretation. The items you requested in your outline marked A. 2. a. 1, 2, 3, and A. 2. b. are those that were primarily responsible for the confusion and were therefore phased out of the summary page. However, the items in your outline marked A. 1. a, b, c (the MG_MID and the LOG10 values for every cell line at the GI50, TGI, and LC50 levels of effect) continue to be available in the Mean Graphs.

If I can be of any further assistance, please let me know.

Sincerely,

A handwritten signature in cursive script, reading "Saul A. Schepartz".

Saul A. Schepartz, Ph.D.
Deputy Associate Director
Developmental Therapeutics Program
Division of Cancer Treatment
National Cancer Institute

cc: Dr. Broder
Dr. Chabner

National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results










NSC: 19893 -G/10	Experiment ID: 9111SR43	Test Type: 8	Units: Molar
Report Date: December 2, 1991	Test Date: November 4, 1991	QNS: SHP	MC:
COMI: 911058	Stain Reagent: PROTEIN-51	SSPL: Q87M	

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50	
			-6.6	-5.6	-4.6	-3.6	-2.6	-6.6	-5.6	-4.6	-3.6	-2.6				
Leukemia																
CJRF-CEM	0.438	1.458	1.328	1.139	0.937	0.852	0.700	67	69	49	44	26	2.01E-05	>2.50E-03	>2.50E-03	
HL-60(TB)	0.374	1.166	0.975	0.866	0.734	0.686	0.510	76	62	45	39	17	1.34E-05	>2.50E-03	>2.50E-03	
K-562	0.255	1.165	1.118	1.030	0.746	0.553	0.596	95	85	54	44	37	6.10E-05	>2.50E-03	>2.50E-03	
MOLT-4	0.516	1.700	1.667	1.480	0.989	0.776	0.744	97	81	40	22	19	1.43E-05	>2.50E-03	>2.50E-03	
RPMI-6226	0.406	1.159	0.936	0.816	0.725	0.650	0.564	71	55	42	32	21	6.06E-06	>2.50E-03	>2.50E-03	
SR	0.323	1.219	1.111	1.079	0.680	0.506	0.460	68	84	40	20	15	1.48E-05	>2.50E-03	>2.50E-03	
Non-Small Cell Lung Cancer																
EKVX	0.647	1.522	1.551	1.397	1.203	1.164	0.982	103	66	64	59	38	6.62E-04	>2.50E-03	>2.50E-03	
HOP-62	0.490	1.318	1.361	1.153	0.749	0.732	0.597	105	80	31	29	13	1.03E-05	>2.50E-03	>2.50E-03	
NCI-H226	0.678	1.136	1.150	1.155	1.005	0.994	0.882	103	104	71	69	45	1.50E-03	>2.50E-03	>2.50E-03	
NCI-H23	0.595	1.507	1.439	1.155	0.748	0.626	0.775	92	61	17	25	20	4.50E-06	>2.50E-03	>2.50E-03	
NCI-H322M	0.566	1.521	1.336	1.155	1.094	1.002	0.891	81	62	55	46	34	8.90E-05	>2.50E-03	>2.50E-03	
NCI-H460	0.242	1.769	1.142	0.514	0.370	0.178	0.141	59	18	8	-27	-42	4.12E-07	4.34E-05	>2.50E-03	
NCI-H522	0.581	1.391	1.391	1.200	0.924	0.657	0.413	100	76	42	9	-29	1.50E-05	4.40E-04	>2.50E-03	
LXFL 529	0.431	1.658	1.542	1.352	1.016	0.650	0.753	91	75	48	34	26	2.06E-05	>2.50E-03	>2.50E-03	
Small Cell Lung Cancer																
DMS 114	0.670	2.006	2.017	1.685	1.531	1.221	1.034	101	76	64	41	27	1.05E-04	>2.50E-03	>2.50E-03	
DMS 273	0.253	1.725	1.561	1.103	0.735	0.558	0.470	89	58	33	21	15	5.10E-06	>2.50E-03	>2.50E-03	
Colon Cancer																
COLO 205	0.278		2.003	1.602	1.369	1.148	1.067									
DLD-1	0.167	0.925	0.771	0.547	0.381	0.318	0.187	60	50	28	20	3	2.54E-06	>2.50E-03	>2.50E-03	
HCC-2998	0.581	1.900	1.028	0.905	0.879	0.762	0.656	34	25	23	14	6	<2.50E-07	>2.50E-03	>2.50E-03	
HCT-116	0.206	1.669	1.544	1.022	0.626	0.362	0.257	90	55	28	11	3	3.86E-06	>2.50E-03	>2.50E-03	
HT29	0.197	1.520	1.249	0.993	0.646	0.513	0.350	79	60	34	24	12	6.08E-06	>2.50E-03	>2.50E-03	
KM12	0.348	1.512	1.340	1.007	0.873	0.715	0.510	85	57	45	31	14	9.40E-06	>2.50E-03	>2.50E-03	
KM20L2	0.640	1.854	1.531	1.317	1.069	0.983	0.805	73	56	35	26	14	4.78E-06	>2.50E-03	>2.50E-03	
SW-620	0.318	1.418	1.341	0.965	0.646	0.584	0.551	93	59	30	24	21	5.05E-06	>2.50E-03	>2.50E-03	
CNS Cancer																
SF-268	0.523	1.396	1.299	1.194	0.965	0.816	0.778	69	77	51	34	29	2.72E-05	>2.50E-03	>2.50E-03	
SF-295	0.341	1.231	1.275	1.143	0.706	0.532	0.576	105	90	41	21	26	1.64E-05	>2.50E-03	>2.50E-03	
SNB-19	0.438	1.287	1.269	1.256	0.951	0.835	0.732	100	96	60	47	35	1.45E-04	>2.50E-03	>2.50E-03	
SNB-75	0.576	0.956	0.963	0.946	0.825	0.748	0.634	102	97	66	45	15	1.49E-04	>2.50E-03	>2.50E-03	
U251	0.461	1.587	1.505	1.350	1.006	0.845	0.489	93	79	48	34	2	2.21E-05	>2.50E-03	>2.50E-03	
Melanoma																
LOX IMVI	0.261	1.468	1.385	0.882	0.595	0.402	0.245	93	51	28	12	-6	2.87E-06	1.11E-03	>2.50E-03	
MALME-3M	0.545	1.056	1.013	0.877	0.828	0.776	0.576	91	65	55	45	6	8.44E-05	>2.50E-03	>2.50E-03	
M14	0.167	0.627	0.618	0.509	0.426	0.394	0.320	98	74	56	49	33	1.93E-04	>2.50E-03	>2.50E-03	
M19-MEL	0.438	1.975	1.638	1.348	1.106	0.983	0.785	78	59	43	35	23	9.61E-06	>2.50E-03	>2.50E-03	
SK-MEL-28	0.445	0.847	0.896	0.833	0.681	0.703	0.673	112	97	59	64	57	>2.50E-03	>2.50E-03	>2.50E-03	
SK-MEL-5	0.422	1.563	1.468	1.243	1.000	0.758	0.176	92	72	51	29	-58	2.68E-05	5.41E-04	2.01E-03	
UACC-257	0.573	1.503	1.519	1.349	1.075	0.937	0.597	102	83	54	39	3	4.59E-05	>2.50E-03	>2.50E-03	
UACC-62	0.637	1.337	1.359	1.229	1.014	0.854	0.329	103	85	54	31	-48	3.69E-05	6.15E-04	>2.50E-03	
Ovarian Cancer																
IGROV1	0.830	1.678	1.670	1.693	1.365	1.209	0.787	99	102	63	45	-5	1.28E-04	1.97E-03	>2.50E-03	
OVCAR-3	0.464	1.219	1.202	1.105	0.959	0.721	0.524	98	85	66	34	8	7.79E-05	>2.50E-03	>2.50E-03	
OVCAR-4	0.678	1.673	1.587	1.459	1.242	1.107	0.720	91	79	57	43	4	7.74E-05	>2.50E-03	>2.50E-03	
OVCAR-5	0.852	1.061	1.046	1.045	0.990	0.884	0.380	92	92	66	15	-55	5.16E-05	4.11E-04	2.10E-03	
OVCAR-8	0.289	1.245	1.206	1.002	0.661	0.576	0.447	96	75	39	30	17	1.22E-05	>2.50E-03	>2.50E-03	
SK-OV-3	1.592	1.971	2.086	1.929	1.931	1.599	1.448	130	89	89	2	-9	7.05E-05	3.69E-04	>2.50E-03	
Renal Cancer																
A498	0.785	1.347	1.303	1.092	1.044	0.959	0.708	92	55	46	31	-10	8.55E-06	1.44E-03	>2.50E-03	
ACHN	0.638	1.783	1.728	1.214	1.036	0.964	0.576	95	50	35	28	-10	2.61E-06	1.39E-03	>2.50E-03	
CAKI-1	0.625	1.555	1.576	1.408	0.979	0.887	0.772	102	84	38	28	16	1.38E-05	>2.50E-03	>2.50E-03	
RXF-393	0.465	0.773	0.778	0.797	0.723	0.666	0.388	102	108	64	65	-17	3.84E-04	1.57E-03	>2.50E-03	
RXF-631	0.506	1.662	1.427	1.118	0.933	0.760	0.714	80	53	37	22	18	3.83E-06	>2.50E-03	>2.50E-03	
SN12C	0.549	1.645	1.613	1.451	1.191	1.032	0.980	97	82	59	44	39	9.78E-05	>2.50E-03	>2.50E-03	
TK-10	1.597		1.597	1.571	1.533	1.428	1.136									
UO-31	0.636	1.352	1.334	1.172	0.994	0.794	0.326	97	75	50	22	-49	2.51E-05	5.13E-04	>2.50E-03	

Dose Response Curves

Report Date: December 2, 1991

Test Date: November 4, 1991



NCI Developmental Therapeutics Program Dose Response Matrix

NSC: 19893 -G/10

Exp. ID: 9111SR43

Test Date: November 4, 1991

Stain: PROTEIN-51

Report Date: December 2, 1991


SSPL: Q87M

Log₁₀ Concentration (Molar)
PG (-5.6) -2.6 -3.6 -4.6 -5.6 -6.6


Panel/Cell Line

Log₁₀ GI50

GI50



Cell Line	Log ₁₀ GI50
Leukemia	
CCRF-CEM	-4.66
HL-60(TB)	-4.87
K-562	-4.21
MOLT-4	-4.84
RPMI-8226	-5.22
SR	-4.83
Non-Small Cell Lung Cancer	
EKVX	-3.17
HOP-62	-4.99
NCI-H226	-2.82
NCI-H23	-5.35
NCI-H322M	-4.05
NCI-H460	-6.39
NCI-H522	-4.82
LXFL 529	-4.69
Small Cell Lung Cancer	
DMS 114	-3.98
DMS 273	-5.29
• Colon Cancer	
COLO 205	
DLD-1	-5.60
HCC-2998	< -6.60
HCT-116	-5.41
HT29	-5.22
KM12	-5.03
KM20L2	-5.32
SW-620	-5.30
CNS Cancer	
SF-268	-4.57
SF-295	-4.79
SNB-19	-3.84
SNB-75	-3.83
U251	-4.66
Melanoma	
LOX IMVI	-5.54
MALME-3M	-4.07
M14	-3.71
M19-MEL	-5.02
SK-MEL-28	> -2.60
SK-MEL-5	-4.57
UACC-257	-4.34
UACC-62	-4.43
Ovarian Cancer	
IGROV1	-3.89
OVCAR-3	-4.11
OVCAR-4	-4.11
OVCAR-5	-4.29
OVCAR-8	-4.91
SK-OV-3	-4.15
Renal Cancer	
A498	-5.07
ACHN	-5.58
CAKI-1	-4.86
RXF-393	-3.42
RXF-631	-5.42
SN12C	-4.01
TK-10	
UO-31	-4.60



PG > GI50
PG ≤ GI50
PG ≤ TGI
PG ≤ LC50

D_{GI50} = 52.0 (-4.6)
D_{TGI} = 40.0 (-2.6)
D_{LC50} = 14.0 (-2.6)
D_H = 76.19 (-5.6)

MG_MID GI50 = -4.63
Delta = 1.97
Range = 4.00
MGD_H = 79.59

National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results

NSC: 19893 -G/10	Experiment ID: 9111SC26	Test Type: 8	Units: Molar
Report Date: December 2, 1991	Test Date: November 12, 1991	QNS: SHP	MC:
COMI: 911058	Stain Reagent: PROTEIN-51	SSPL: Q87M	

Panel/Cell Line	Time	Log10 Concentration											GI50	TGI	LC50	
		Zero	Ctrl	Mean Optical Densities			Percent Growth									
				-6.6	-5.6	-4.6	-3.6	-2.6	-1.6	-0.6	0.4	1.4	2.4	3.4	4.4	5.4
Leukemia																
CCRF-CEM	0.256	0.901	0.943	0.859	0.844	0.431	0.397	107	94	60	27	23	5.10E-05	>2.50E-03	>2.50E-03	
HL-60 (TB)	0.369	1.816	1.822	1.475	0.999	0.733	0.534	100	76	43	24	10	1.51E-05	>2.50E-03	>2.50E-03	
K-562	0.129	0.856	0.801	0.786	0.459	0.261	0.224	93	91	45	18	13	1.96E-05	>2.50E-03	>2.50E-03	
MOLT-4	0.401	1.522	1.534	1.411	0.778	0.394	0.444	101	90	34	-2	4	1.26E-05		>2.50E-03	
RFMI-8226	0.330	1.032	1.041	0.738	0.542	0.370	0.316	101	58	30	6	-4	4.90E-06	9.36E-04	>2.50E-03	
SR	0.391	1.670	1.710	1.672	1.023	0.504	0.391	103	100	49	9	.	2.44E-05	>2.50E-03	>2.50E-03	
Non-Small Cell Lung Cancer																
A549/ATCC	0.431	1.665	1.734	1.414	0.759	0.662	0.407	106	80	27	19	-6	9.05E-06	1.46E-03	>2.50E-03	
ENVX	0.857	1.601	1.650	1.620	1.332	1.210	1.100	107	103	64	47	33	1.74E-04	>2.50E-03	>2.50E-03	
HOP-62	0.532	1.508	1.496	1.530	0.772	0.756	0.602	99	102	25	23	7	1.18E-05	>2.50E-03	>2.50E-03	
HOP-92	0.933	1.161	1.171	1.121	0.985	1.017	0.960	104	82	23	37	12	6.73E-06	>2.50E-03	>2.50E-03	
NCI-H226	0.802	1.546	1.502	1.467	1.317	1.234	1.192	94	89	69	58	52	>2.50E-03	>2.50E-03	>2.50E-03	
NCI-H23	0.424	1.227	1.237	1.099	0.757	0.704	0.587	101	84	41	35	20	1.58E-05	>2.50E-03	>2.50E-03	
NCI-H322M	0.636	1.624	1.619	1.409	1.119	0.988	0.993	99	76	49	36	36	2.29E-05	>2.50E-03	>2.50E-03	
NCI-H460	0.228	1.634	1.545	1.131	0.454	0.270	0.152	94	64	16	3	-34	4.94E-06	3.02E-04	>2.50E-03	
LXFL 529	0.379	1.244	1.227	1.188	0.933	0.674	0.517	98	94	64	34	16	7.39E-05	>2.50E-03	>2.50E-03	
Small Cell Lung Cancer																
DMS 114	0.558	1.473	1.446	1.391	1.075	0.923	0.771	97	91	57	40	23	6.14E-05	>2.50E-03	>2.50E-03	
DMS 273	0.160	0.895	1.016	0.943	0.363	0.259	0.222	116	107	28	13	8	1.30E-05	>2.50E-03	>2.50E-03	
Colon Cancer																
COLO 205	0.314	1.117	1.165	0.965	0.689	0.530	0.314	106	81	47	27	0	2.00E-05	2.47E-03	>2.50E-03	
DLD-1	0.426	1.677	1.857	1.523	0.971	0.794	0.616	99	76	38	25	13	1.16E-05	>2.50E-03	>2.50E-03	
HCC-2998	0.564	1.653	1.423	0.878	0.755	0.738	0.673	79	29	18	16	10	9.41E-07	>2.50E-03	>2.50E-03	
HCT-116	0.328	1.955	1.910	1.728	0.724	0.156	0.053	97	86	24	-52	-84	9.59E-06	5.18E-05	2.32E-04	
HCT-15	0.524	.	2.334	2.027	1.409	1.137	0.711	
HT29	0.364	1.623	1.712	1.546	0.933	0.792	0.615	92	81	39	29	17	1.37E-05	>2.50E-03	>2.50E-03	
KM12	0.248	1.072	1.016	0.813	0.444	0.395	0.305	93	69	24	16	7	6.49E-06	>2.50E-03	>2.50E-03	
SW-620	0.205	1.227	1.197	1.164	0.606	0.482	0.398	97	94	39	27	19	1.59E-05	>2.50E-03	>2.50E-03	
CNS Cancer																
SF-268	0.698	1.743	1.739	1.745	1.224	0.950	0.985	100	101	50	24	27	2.58E-05	>2.50E-03	>2.50E-03	
SF-295	0.536	1.703	1.601	1.608	1.100	0.822	0.826	91	92	48	25	25	2.29E-05	>2.50E-03	>2.50E-03	
SNB-19	0.738	1.766	1.693	1.708	1.312	1.125	0.984	93	94	56	38	24	5.22E-05	>2.50E-03	>2.50E-03	
SNB-75	0.469	0.828	0.800	0.836	0.677	0.591	0.521	92	102	58	34	14	5.39E-05	>2.50E-03	>2.50E-03	
U251	0.285	1.464	1.471	1.396	1.041	0.669	0.493	101	94	64	33	18	7.00E-05	>2.50E-03	>2.50E-03	
XF 498	0.545	0.666	0.654	0.597	0.548	0.485	0.372	90	43	2	-11	-32	1.76E-06	3.59E-05	>2.50E-03	
Melanoma																
LOX IMVI	0.357	1.768	1.773	1.628	0.806	0.512	0.313	100	90	32	11	-12	1.22E-05	7.40E-04	>2.50E-03	
MALME-3M	0.731	1.561	1.532	1.397	1.195	1.155	0.911	97	80	56	51	22	2.72E-04	>2.50E-03	>2.50E-03	
M14	0.372	0.922	0.927	0.887	0.703	0.635	0.535	101	94	60	48	30	1.64E-04	>2.50E-03	>2.50E-03	
M19-MEL	0.303	1.107	1.095	0.927	0.682	0.602	0.463	99	75	47	37	20	2.02E-05	>2.50E-03	>2.50E-03	
SK-MEL-2	0.524	1.764	1.733	1.822	1.618	1.340	1.136	98	113	88	66	49	2.29E-03	>2.50E-03	>2.50E-03	
SK-MEL-28	0.477	1.276	1.277	1.138	0.835	0.771	0.717	100	83	45	37	30	1.82E-05	>2.50E-03	>2.50E-03	
SK-MEL-5	0.543	.	2.220	1.975	1.357	1.039	0.218	
UACC-257	0.805	1.718	1.745	1.752	1.324	1.140	0.936	103	104	57	37	14	5.47E-05	>2.50E-03	>2.50E-03	
UACC-62	0.553	1.594	1.558	1.450	1.081	0.931	0.364	96	86	51	36	-30	2.81E-05	8.74E-04	>2.50E-03	
Ovarian Cancer																
IGROV1	0.663	1.650	1.628	1.622	1.211	1.064	0.729	98	97	55	41	7	5.65E-05	>2.50E-03	>2.50E-03	
OVCAR-3	0.666	1.316	1.331	1.059	0.869	0.600	0.434	102	60	31	-10	-35	5.69E-06	1.43E-04	>2.50E-03	
OVCAR-4	0.555	1.191	1.174	1.026	0.845	0.722	0.462	97	74	46	26	-17	1.76E-05	1.02E-03	>2.50E-03	
OVCAR-5	0.450	1.235	1.211	1.183	1.075	0.972	0.601	97	93	80	66	19	5.57E-04	>2.50E-03	>2.50E-03	
OVCAR-8	0.379	1.386	1.321	1.210	0.757	0.641	0.535	94	82	38	26	15	1.32E-05	>2.50E-03	>2.50E-03	
Renal Cancer																
786-0	0.200	1.247	1.279	1.180	0.787	0.642	0.295	103	94	56	42	9	6.86E-05	>2.50E-03	>2.50E-03	
A498	0.500	0.988	0.944	0.892	0.715	0.628	0.356	91	80	44	26	-29	1.71E-05	7.46E-04	>2.50E-03	
ACHN	0.500	1.434	1.366	1.239	0.772	0.678	0.432	93	79	29	19	-14	9.55E-06	9.58E-04	>2.50E-03	
CAKI-1	0.624	1.361	1.373	1.336	0.935	0.796	0.591	102	97	42	23	-5	1.80E-05	1.63E-03	>2.50E-03	
RXF-393	0.506	1.001	1.013	1.009	0.874	0.695	0.374	102	102	74	38	-26	1.17E-04	9.81E-04	>2.50E-03	
RXF-631	0.335	1.157	1.110	0.830	0.579	0.525	0.479	94	60	30	23	18	5.41E-06	>2.50E-03	>2.50E-03	
SN12C	0.599	1.253	1.278	1.140	0.904	0.759	0.658	104	83	47	24	9	2.02E-05	>2.50E-03	>2.50E-03	
TK-10	0.960	1.740	1.725	1.598	1.375	1.340	0.864	98	82	53	49	-8	1.29E-04	1.82E-03	>2.50E-03	
UO-31	0.835	1.689	1.665	1.643	1.204	0.820	0.302	97	95	43	-2	-64	1.85E-05	2.26E-04	1.50E-03	

National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results

NSC: 19893 -G/10	Experiment ID: 9111SC25	Test Type: 8	Units: Molar
Report Date: December 2, 1991	Test Date: November 4, 1991	QNS: SHP	MC:
COMI: 911058	Stain Reagent: PROTEIN-51	SSPL: Q87M	

Panel/Cell Line	Time Zero	Log10 Concentration										GI50	TGI	LC50	
		Ctrl	-6.6	-5.6	-4.6	-3.6	-2.6	-6.6	-5.6	-4.6	-3.6				-2.6
Leukemia															
CCRF-CEM	0.217	0.975	0.981	0.962	0.643	0.582	0.373	101	98	56	35	21	5.35E-05	>2.50E-03	>2.50E-03
HL-60(TB)	0.479	2.047	2.009	1.639	1.072	0.699	0.649	96	74	36	27	11	1.15E-05	>2.50E-03	>2.50E-03
K-562	0.095	0.821	0.853	0.846	0.445	0.267	0.214	104	104	48	26	16	2.33E-05	>2.50E-03	>2.50E-03
MOLT-4	0.362	1.716	1.742	1.724	0.732	0.326	0.496	102	101	27	-10	3	1.23E-05	.	>2.50E-03
RFMI-8226	0.349	1.446	1.491	0.917	0.740	0.629	0.419	104	52	36	25	6	3.23E-06	>2.50E-03	>2.50E-03
SR	0.246	1.477	1.501	1.366	0.766	0.266	0.201	102	91	42	.	.	1.73E-05	>2.50E-05	>2.50E-05
Non-Small Cell Lung Cancer															
A549/ATCC	0.441	1.670	1.593	1.444	0.822	0.692	0.353	94	82	31	20	-20	1.05E-05	6.01E-04	>2.50E-03
EKVX	0.687	1.351	1.326	1.420	1.205	1.145	1.015	96	111	78	69	49	2.35E-03	>2.50E-03	>2.50E-03
HOP-62	0.641	1.566	1.582	1.500	0.796	0.773	0.564	102	93	17	14	-12	9.14E-06	6.73E-04	>2.50E-03
HOP-92	0.870	1.310	1.319	1.313	1.219	1.353	1.230	102	101	79	110	62	>2.50E-03	>2.50E-03	>2.50E-03
NCI-H226	1.066	1.354	1.352	1.339	1.308	1.199	1.020	100	95	64	46	-4	1.95E-04	2.04E-03	>2.50E-03
NCI-H23	0.598	1.418	1.257	1.238	0.928	0.828	0.728	80	76	40	28	16	1.36E-05	>2.50E-03	>2.50E-03
NCI-H322M	0.675	1.554	1.634	1.457	1.254	1.106	0.960	109	69	66	49	32	2.19E-04	>2.50E-03	>2.50E-03
NCI-H460	0.178	1.657	1.583	1.173	0.538	0.363	0.292	95	67	24	13	6	6.31E-06	>2.50E-03	>2.50E-03
NCI-H522	0.716	1.317	1.386	1.325	1.095	0.834	0.560	111	101	63	20	-19	4.99E-05	5.06E-04	>2.50E-03
LMFL 529	0.444	1.615	1.623	1.651	1.222	0.852	0.730	101	103	66	35	24	8.26E-05	>2.50E-03	>2.50E-03
Small Cell Lung Cancer															
DMS 114	0.568	1.588	1.554	1.451	1.170	0.955	0.744	97	87	59	38	17	6.67E-05	>2.50E-03	>2.50E-03
DMS 273	0.167	1.174	1.164	0.981	0.447	0.285	0.198	99	81	28	12	3	9.51E-06	>2.50E-03	>2.50E-03
Colon Cancer															
COLO 205	0.344	1.335	1.331	1.044	0.754	0.611	0.396	100	71	41	27	5	1.26E-05	>2.50E-03	>2.50E-03
DLD-1	0.464	1.937	1.959	1.451	1.132	0.939	0.705	101	67	45	32	16	1.52E-05	>2.50E-03	>2.50E-03
HCC-2998	0.712	1.786	1.627	1.018	0.876	0.919	0.764	85	28	15	19	5	1.04E-06	>2.50E-03	>2.50E-03
HCT-116	0.258	1.469	1.466	1.280	0.607	0.161	0.138	100	64	29	-38	-47	1.04E-05	6.79E-05	>2.50E-03
HCT-15	0.405	1.633	1.802	1.644	1.031	0.865	0.549	98	67	44	32	10	1.79E-05	>2.50E-03	>2.50E-03
HT29	0.159	0.832	0.825	0.661	0.435	0.298	0.225	99	78	41	21	10	1.42E-05	>2.50E-03	>2.50E-03
KM12	0.328	1.080	0.971	0.903	0.596	0.480	0.355	85	76	36	20	4	1.11E-05	>2.50E-03	>2.50E-03
KM20L2	0.302	1.117	1.122	1.132	1.133	1.173	1.030	101	102	102	107	89	>2.50E-03	>2.50E-03	>2.50E-03
SW-620	0.259	1.230	1.219	1.158	0.666	0.494	0.299	99	93	42	24	4	1.73E-05	>2.50E-03	>2.50E-03
CNS Cancer															
SF-268	0.775	1.859	1.894	1.945	1.413	1.200	1.170	103	108	59	39	36	7.03E-05	>2.50E-03	>2.50E-03
SF-295	0.246	0.626	0.571	0.656	0.540	0.378	0.315	86	108	77	35	18	1.10E-04	>2.50E-03	>2.50E-03
SF-539	0.977	2.071	1.967	1.647	1.411	1.164	0.824	90	80	40	17	-16	1.37E-05	8.30E-04	>2.50E-03
SNB-19	0.989	1.803	1.852	1.844	1.695	1.504	1.462	106	105	67	63	58	>2.50E-03	>2.50E-03	>2.50E-03
SNB-75	0.672	0.929	0.977	0.961	0.886	0.761	0.661	119	112	83	34	-2	1.19E-04	2.24E-03	>2.50E-03
U251	0.308	1.248	1.263	1.276	1.298	1.241	1.051	104	103	105	99	79	>2.50E-03	>2.50E-03	>2.50E-03
XF 498	0.560	0.781	0.750	0.741	0.640	0.609	0.424	86	82	36	22	-24	1.23E-05	7.50E-04	>2.50E-03
Melanoma															
LOX IMVI	0.456	1.998	2.007	1.947	0.980	0.633	0.366	101	97	34	11	-20	1.39E-05	5.81E-04	>2.50E-03
MALME-3M	0.739	1.600	1.551	1.275	1.098	1.049	0.878	94	62	42	36	16	9.87E-06	>2.50E-03	>2.50E-03
M14	0.429	1.467	1.567	1.454	1.039	0.887	0.748	110	99	59	44	31	9.95E-05	>2.50E-03	>2.50E-03
M19-MEL	0.318	1.215	1.220	0.981	0.747	0.642	0.421	101	74	48	36	11	2.06E-05	>2.50E-03	>2.50E-03
SK-MEL-2	0.653	1.516	1.575	1.518	1.237	1.122	0.927	107	100	68	54	32	3.66E-04	>2.50E-03	>2.50E-03
SK-MEL-28	0.618	1.355	1.392	1.257	0.875	0.895	0.799	105	87	48	38	25	2.27E-05	>2.50E-03	>2.50E-03
SK-MEL-5	0.551	1.794	1.805	1.492	1.056	0.760	0.095	101	76	41	17	-63	1.35E-05	3.69E-04	1.17E-03
UACC-257	0.449	1.194	1.266	1.165	0.842	0.649	0.543	110	99	53	27	13	3.20E-05	>2.50E-03	>2.50E-03
UACC-62	0.566	1.679	1.644	1.467	1.136	0.935	0.331	97	81	51	33	-42	2.90E-05	6.95E-04	>2.50E-03
Ovarian Cancer															
IGROV1	0.740	1.748	1.731	1.750	1.378	1.196	0.685	98	100	63	45	-7	1.36E-04	1.81E-03	>2.50E-03
OVCA3-3	0.760	1.692	1.641	1.563	1.329	1.012	0.615	95	86	61	27	-19	5.29E-05	9.65E-04	>2.50E-03
OVCA3-4	0.556	1.354	1.366	1.191	1.017	0.913	0.639	101	80	58	45	10	9.77E-05	>2.50E-03	>2.50E-03
OVCA3-5	0.570	1.164	1.173	1.142	1.143	1.117	1.083	101	96	96	92	86	>2.50E-03	>2.50E-03	>2.50E-03
OVCA3-8	0.370	1.472	1.372	1.303	0.784	0.686	0.516	91	85	39	29	13	1.36E-05	>2.50E-03	>2.50E-03
SK-OV-3	0.676	1.246	1.242	1.204	1.099	0.990	0.830	99	93	74	55	27	3.61E-04	>2.50E-03	>2.50E-03
Renal Cancer															
786-0	0.259	1.180	1.132	0.941	0.663	0.530	0.174	95	74	44	29	-33	1.57E-05	7.40E-04	>2.50E-03
A498	0.724	1.737	1.768	1.364	1.269	1.071	0.642	103	63	54	34	-11	3.89E-05	1.41E-03	>2.50E-03
ACHN	0.263	1.204	1.213	1.118	0.692	0.590	0.378	101	91	46	35	12	1.99E-05	>2.50E-03	>2.50E-03
CAKI-1	0.538	1.514	1.470	1.579	0.959	0.801	0.636	96	107	43	27	10	1.95E-05	>2.50E-03	>2.50E-03
RXF-393	0.887	1.102	1.069	1.039	0.956	0.894	0.607	84	71	32	3	-32	8.63E-06	3.06E-04	>2.50E-03
RXF-631	0.400	1.155	1.179	0.932	0.662	0.577	0.526	103	70	35	23	17	9.30E-06	>2.50E-03	>2.50E-03
SN12C	0.715	1.814	1.850	1.780	1.355	1.175	1.037	103	97	58	42	29	7.91E-05	>2.50E-03	>2.50E-03
TK-10	0.827	1.514	1.486	1.366	1.194	1.146	0.750	96	78	53	46	-9	7.86E-05	1.70E-03	>2.50E-03
VO-31	1.003	1.488	1.541	1.496	1.241	0.813	0.301	111	102	49	-19	-70	2.40E-05	1.32E-04	1.61E-03

National Cancer Institute Developmental Therapeutics Program

Dose Response Curves










NSC: 19893 -G/10

SSPL: Q87M

Exp. ID: 9111SC26

Report Date: December 2, 1991

Test Date: November 12, 1991



National Cancer Institute Developmental Therapeutics Program

Dose Response Curves










NSC: 19893 -G/10

SSPL: Q87M

Exp. ID: 9111SC25

Report Date: December 2, 1991

Test Date: November 4, 1991



National Cancer Institute Developmental Therapeutics Program

Mean Graphs

NSC: 19893 -G/10 Units: Molar
 Report Date: December 2, 1991
 SSPL: Q87M Exp. ID: 9111SC26
 Test Date: November 12, 1991

Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-4.29	0.00	> -2.60	0.00	> -2.60	0.00
HL-60(TB)	-4.82	-0.20	> -2.60	0.00	> -2.60	0.00
K-562	-4.70	-0.20	> -2.60	0.00	> -2.60	0.00
MOLT-4	-4.89	-0.20	> -2.60	0.00	> -2.60	0.00
RPNH-8226	-5.31	-0.20	-3.03	-0.20	> -2.60	0.00
SR	-4.61	-0.20	> -2.60	0.00	> -2.60	0.00
Non-Small Cell Lung Cancer						
A549(ATCC)	-5.04	-0.20	-2.84	-0.20	> -2.60	0.00
BEVX	-3.76	-0.20	> -2.60	0.00	> -2.60	0.00
HOP-62	-4.93	-0.20	> -2.60	0.00	> -2.60	0.00
HOP-92	-5.00	-0.20	> -2.60	0.00	> -2.60	0.00
NCL-H1226	> -2.60	-0.20	> -2.60	0.00	> -2.60	0.00
NCL-H123	-4.80	-0.20	> -2.60	0.00	> -2.60	0.00
NCL-H1224M	-4.64	-0.20	> -2.60	0.00	> -2.60	0.00
NCL-H460	-5.31	-0.20	-3.52	-0.20	> -2.60	0.00
LXPL 529	-4.13	-0.20	> -2.60	0.00	> -2.60	0.00
Small Cell Lung Cancer						
DMS 114	-4.21	-0.20	> -2.60	0.00	> -2.60	0.00
DMS 273	-4.89	-0.20	> -2.60	0.00	> -2.60	0.00
Colon Cancer						
COLO 205	-4.70	-0.20	-2.61	-0.20	> -2.60	0.00
DLD-1	-4.93	-0.20	> -2.60	0.00	> -2.60	0.00
HCC-2998	-6.03	-0.20	> -2.60	0.00	> -2.60	0.00
HCT-116	-5.02	-0.20	-4.29	-0.20	-3.63	-0.20
HCT-115	-4.86	-0.20	> -2.60	0.00	> -2.60	0.00
HT79	-5.19	-0.20	> -2.60	0.00	> -2.60	0.00
KM12	-4.80	-0.20	> -2.60	0.00	> -2.60	0.00
SW-620	-4.59	-0.20	> -2.60	0.00	> -2.60	0.00
CNS Cancer						
SP-266	-4.64	-0.20	> -2.60	0.00	> -2.60	0.00
SP-295	-4.28	-0.20	> -2.60	0.00	> -2.60	0.00
SNB-19	-4.27	-0.20	> -2.60	0.00	> -2.60	0.00
SNB-75	-4.15	-0.20	> -2.60	0.00	> -2.60	0.00
U251	-4.15	-0.20	> -2.60	0.00	> -2.60	0.00
XP-498	-5.75	-0.20	-4.44	-0.20	> -2.60	0.00
Melanoma						
LOX IMVI	-4.91	-0.20	-3.13	-0.20	> -2.60	0.00
MALME-3M	-3.57	-0.20	> -2.60	0.00	> -2.60	0.00
M14	-3.79	-0.20	> -2.60	0.00	> -2.60	0.00
M19-MEL	-4.69	-0.20	> -2.60	0.00	> -2.60	0.00
SK-MEL-2	-2.64	-0.20	> -2.60	0.00	> -2.60	0.00
SK-MEL-28	-4.74	-0.20	> -2.60	0.00	> -2.60	0.00
SK-MEL-5	-4.74	-0.20	> -2.60	0.00	> -2.60	0.00
UACC-257	-4.26	-0.20	> -2.60	0.00	> -2.60	0.00
UACC-62	-4.55	-0.20	-3.06	-0.20	> -2.60	0.00
Ovarian Cancer						
IGROV1	-4.23	-0.20	> -2.60	0.00	> -2.60	0.00
OVCAK-3	-5.24	-0.20	-3.84	-0.20	> -2.60	0.00
OVCAK-4	-4.75	-0.20	-2.99	-0.20	> -2.60	0.00
OVCAK-5	-3.25	-0.20	> -2.60	0.00	> -2.60	0.00
OVCAK-8	-4.88	-0.20	> -2.60	0.00	> -2.60	0.00
Renal Cancer						
786-0	-4.16	-0.20	> -2.60	0.00	> -2.60	0.00
A498	-4.77	-0.20	-3.13	-0.20	> -2.60	0.00
ACHN	-5.02	-0.20	-3.02	-0.20	> -2.60	0.00
CARK-1	-4.74	-0.20	-2.79	-0.20	> -2.60	0.00
RXF-393	-3.93	-0.20	-3.01	-0.20	> -2.60	0.00
RXF-631	-5.27	-0.20	> -2.60	0.00	> -2.60	0.00
SNI-2C	-4.69	-0.20	> -2.60	0.00	> -2.60	0.00
TK-10	-3.89	-0.20	-2.74	-0.20	> -2.60	0.00
UD-31	-4.73	-0.20	-3.64	-0.20	-2.82	-0.20
MG_MHD						
Della	-4.58	-0.20	-2.81	-0.20	-2.63	-0.20
Range	1.45	-0.20	1.64	-0.20	1.01	-0.20
	3.42	-0.20	1.84	-0.20	1.03	-0.20

National Cancer Institute Developmental Therapeutics Program

Mean Graphs

NSC: 19893 -G/10


Units: Molar

SSPL: Q87M

Exp. ID: 9111SR43

Report Date: December 2, 1991

Test Date: November 4, 1991



National Cancer Institute Developmental Therapeutics Program

Mean Graphs

NSC: 19893 -G/10 Units: Molar SSPL: Q87M Exp. ID: 9111SC25
 Report Date: December 2, 1991 Test Date: November 4, 1991

Panel/Cell Line	$Log_{10} GI50$	GI50	$Log_{10} TGI$	TGI	$Log_{10} LC50$	LC50
Leukemia						
CCRF-CEM	-4.27		> -2.60		> -2.60	
HL-60(TH)	-4.04		> -2.60		> -2.60	
K-562	-4.63		> -2.60		> -2.60	
MO1-T-4	-4.91		> -2.60		> -2.60	
RPML-8226	-5.49		> -2.60		> -2.60	
SR	-4.76		> -2.60		> -2.60	
Non-Small Cell Lung Cancer						
A549/ATCC	-4.98		-3.10		> -2.60	
ERVX	-2.63		> -2.60		> -2.60	
HOP-62	-5.04		-3.06		> -2.60	
HOP-92	> -2.60		> -2.60		> -2.60	
NCH-H226	-4.71		-2.69		> -2.60	
NCH-H23	-4.86		> -2.60		> -2.60	
NCH-H22M	-3.66		> -2.60		> -2.60	
NCH-H460	-5.20		> -2.60		> -2.60	
NCH-H522	-4.30		-3.09		> -2.60	
LXEL 529	-4.08		> -2.60		> -2.60	
Small Cell Lung Cancer						
DMS 114	-4.18		> -2.60		> -2.60	
DMS 273	-5.02		> -2.60		> -2.60	
Colon Cancer						
COLO 205	-4.90		> -2.60		> -2.60	
DLD-1	-4.82		> -2.60		> -2.60	
HCC-2998	-5.98		> -2.60		> -2.60	
HCT-116	-4.98		-4.17		> -2.60	
HCT-15	-4.75		> -2.60		> -2.60	
HT29	-4.85		> -2.60		> -2.60	
KM12	-4.95		> -2.60		> -2.60	
KM20L2	> -2.60		> -2.60		> -2.60	
SW-620	-4.76		> -2.60		> -2.60	
CNS Cancer						
SF-265	-4.15		> -2.60		> -2.60	
SF-295	-3.96		> -2.60		> -2.60	
SF-539	-4.86		-3.08		> -2.60	
SNB-19	> -2.60		> -2.60		> -2.60	
SNB-75	-3.92		-2.65		> -2.60	
U251	> -2.60		> -2.60		> -2.60	
XE 498	-4.91		-3.12		> -2.60	
Melanoma						
LOX BV1	-4.86		-3.24		> -2.60	
MALME-3M	-5.01		> -2.60		> -2.60	
M14	-4.00		> -2.60		> -2.60	
M19-MEL	-4.69		> -2.60		> -2.60	
SK-MEL-2	-3.41		> -2.60		> -2.60	
SK-MEL-28	-4.64		> -2.60		> -2.60	
SK-MEL-5	-4.87		-3.43		> -2.60	
UACC-257	-4.49		> -2.60		> -2.60	
UACC-62	-4.54		-3.16		> -2.60	
Ovarian Cancer						
IGROV1	-1.87		-2.74		> -2.60	
OVCAR-3	-4.28		-3.02		> -2.60	
OVCAR-4	-4.01		> -2.60		> -2.60	
OVCAR-5	> -2.60		> -2.60		> -2.60	
OVCAR-8	-4.87		> -2.60		> -2.60	
SK-OV-3	-3.42		> -2.60		> -2.60	
Kidney Cancer						
786-O	-4.80		-3.13		> -2.60	
A496	-4.41		-2.85		> -2.60	
ACTH	-4.70		> -2.60		> -2.60	
CAKI-1	-4.71		> -2.60		> -2.60	
RXN-303	-5.06		-3.51		> -2.60	
RXN-631	-5.03		> -2.60		> -2.60	
SN12C	-4.10		> -2.60		> -2.60	
TK-10	-4.10		-2.77		> -2.60	
UO-31	-4.62		-3.88		> -2.60	
MG_MID						
Delta	-4.38		-2.81		> -2.60	
Range	1.60		1.36		0.35	
	3.38		1.57		0.39	

NCI Developmental Therapeutics Program Dose Response Matrix

NSC: 19893 -G/10

Exp. ID: 9111SC25

Test Date: November 4, 1991

Stain: PROTEIN-51

Report Date: December 2, 1991


SSPL: Q87M

Log₁₀ Concentration (Molar)
PG (-4.6) -2.6 -3.6 -4.6 -5.6 -6.6


Panel/Cell Line

Log₁₀ GI50

GI50



Panel/Cell Line	Log ₁₀ GI50
Leukemia	
CCRF-CEM	-4.27
HL-60(TB)	-4.94
K-562	-4.63
MOLT-4	-4.91
RPMI-8226	-5.49
SR	-4.76
Non-Small Cell Lung Cancer	
A549/ATCC	-4.98
EKVX	-2.63
HOP-62	-5.04
HOP-92	> -2.60
NCI-H226	-3.71
NCI-H23	-4.86
NCI-H322M	-3.66
NCI-H460	-5.20
NCI-H522	-4.30
LXFL 529	-4.08
Small Cell Lung Cancer	
DMS 114	-4.18
DMS 273	-5.02
Colon Cancer	
COLO 205	-4.90
DLD-1	-4.82
HCC-2998	-5.98
HCT-116	-4.98
HCT-15	-4.75
HT29	-4.85
KM12	-4.95
KM20L2	> -2.60
SW-620	-4.76
CNS Cancer	
SF-268	-4.15
SF-295	-3.96
SF-539	-4.86
SNB-19	> -2.60
SNB-75	-3.92
U251	> -2.60
XF 498	-4.91
Melanoma	
LOX IMVI	-4.86
MALME-3M	-5.01
M14	-4.00
M19-MEL	-4.69
SK-MEL-2	-3.41
SK-MEL-28	-4.64
SK-MEL-5	-4.87
UACC-257	-4.49
UACC-62	-4.54
Ovarian Cancer	
IGROV1	-3.87
OVCAR-3	-4.28
OVCAR-4	-4.01
OVCAR-5	> -2.60
OVCAR-8	-4.87
SK-OV-3	-3.42
Renal Cancer	
786-0	-4.80
A498	-4.41
ACHN	-4.70
CAKI-1	-4.71
RXF-393	-5.06
RXF-631	-5.03
SN12C	-4.10
TK-10	-4.10
UO-31	-4.62



PG > GI50
 PG ≤ GI50
 PG ≤ TGI
 PG ≤ LC50

$D_{GI50} = 42.0 (-4.6)$
 $D_{TGI} = 28.0 (-2.6)$
 $D_{LC50} = 11.0 (-2.6)$
 $D_H = 41.75 (-4.6)$

$MG_MID\ GI50 = -4.38$
 $\Delta = 1.60$
 $Range = 3.38$
 $MGD_H = 42.90$

NCI Developmental Therapeutics Program Dose Response Matrix


NSC: 19893 -G/10	Exp. ID: 9111SC26
Test Date: November 12, 1991	Stain: PROTEIN-51
Report Date: December 2, 1991	SSPL: Q87M

Log₁₀ Concentration (Molar)
PG (-3.6) -2.6 -3.6 -4.6 -5.6 -6.6


Panel/Cell Line

Log₁₀ GI50



GI50




Leukemia
CCRF-CEM -4.29
HL-60(TB) -4.82
K-562 -4.70
MOLT-4 -4.89
RPMI-8226 -5.31
SR -4.61





Non-Small Cell Lung Cancer
A549/ATCC -5.04
EKVX -3.76
HOP-62 -4.93
HOP-92 -5.06
NCI-H226 > -2.60
NCI-H23 -4.80
NCI-H322M -4.64
NCI-H460 -5.31
LXFL 529 -4.13




Small Cell Lung Cancer
DMS 114 -4.21
DMS 273 -4.89





Colon Cancer
COLO 205 -4.70
DLD-1 -4.93
HCC-2998 -6.03
HCT-116 -5.02
HCT-15
HT29 -4.86
KM12 -5.19
SW-620 -4.80




CNS Cancer
SF-268 -4.59
SF-295 -4.64
SNB-19 -4.28
SNB-75 -4.27
U251 -4.15
XF 498 -5.75




Melanoma
LOX IMVI -4.91
MALME-3M -3.57
M14 -3.79
M19-MEL -4.69
SK-MEL-2 -2.64
SK-MEL-28 -4.74
SK-MEL-5
UACC-257 -4.26
UACC-62 -4.55



Ovarian Cancer
IGROV1 -4.23
OVCAR-3 -5.24
OVCAR-4 -4.75
OVCAR-5 -3.25
OVCAR-8 -4.88



Renal Cancer
786-0 -4.16
A498 -4.77
ACHN -5.02
CAKI-1 -4.74
RXF-393 -3.93
RXF-631 -5.27
SN12C -4.69
TK-10 -3.89
UO-31 -4.73



+4 +3 +2 +1 0 -1 -2 -3 -4

PG > GI50
PG ≤ GI50
PG ≤ TGI
PG ≤ LCS0

D_{GI50} = 42.0 (-4.6)
D_{TGI} = 41.0 (-2.6)
D_{LCS0} = 14.0 (-3.6)
D_H = 57.25 (-3.6)

MG_{MID GI50} = -4.58
Delta = 1.45
Range = 3.42
MG_{DH} = 54.92

National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results


NSC: 631570-W/1	Experiment ID: 9004MD75	Test Type: 8	Units: Molar
Report Date: December 2, 1991	Test Date: April 16, 1990	QNS:	MC:
COMI:	Stain Reagent: PROTEIN-51	SSPL: V27D	

Panel/Cell Line	Time Zero	Log10 Concentration										GI50	TGI	LC50		
		Ctrl	-12.7	-11.7	-10.7	-9.7	-8.7	-12.7	-11.7	-10.7	-9.7				-8.7	
Leukemia																
HL-60(TB)	0.466	1.840	1.570	1.370	2.001	1.599	1.518	102	95	112	104	77	>1.91E-09	>1.91E-09	>1.91E-09	
K-562	0.293	1.562	1.572	1.620	1.676	1.495	1.542	101	105	109	111	96	>1.91E-09	>1.91E-09	>1.91E-09	
KPM1-8226	0.662	2.010	2.036	2.037	2.122	2.105	2.021	102	102	110	108	101	>1.91E-09	>1.91E-09	>1.91E-09	
SR	0.413	0.994	1.039	1.033	1.145	1.108	0.651	106	107	126	120	75	>1.91E-09	>1.91E-09	>1.91E-09	
Non-Small Cell Lung Cancer																
A549/ATCC	0.297	0.998	1.006	1.062	1.015	1.076	1.135	101	109	102	111	120	>1.91E-09	>1.91E-09	>1.91E-09	
EVXV	0.454	0.719	0.628	0.707	0.751	0.763	0.713	66	95	112	116	96	>1.91E-09	>1.91E-09	>1.91E-09	
HOP-18	0.409	0.686	0.706	0.709	0.747	0.751	0.746	107	108	122	123	121	>1.91E-09	>1.91E-09	>1.91E-09	
HOP-62	1.244	1.552	1.563	1.599	1.581	1.582	1.530	103	115	110	110	93	>1.91E-09	>1.91E-09	>1.91E-09	
HOP-92	0.634	0.794	0.818	0.794	0.797	0.802	0.777	115	99	102	104	69	>1.91E-09	>1.91E-09	>1.91E-09	
NCI-H23	0.395	0.861	0.811	0.801	0.844	0.866	0.803	89	67	96	102	68	>1.91E-09	>1.91E-09	>1.91E-09	
NCI-H322M	0.974	1.365	1.415	1.418	1.449	1.508	1.522	107	108	116	130	133	>1.91E-09	>1.91E-09	>1.91E-09	
NCI-H460	0.163	1.152	1.186	1.161	1.148	1.222	1.119	103	101	100	107	97	>1.91E-09	>1.91E-09	>1.91E-09	
NCI-H522	0.346	0.819	0.819	0.772	0.827	0.819	0.724	100	90	102	96	80	>1.91E-09	>1.91E-09	>1.91E-09	
LMFL 529	0.371	1.033	1.051	1.032	1.081	1.074	0.937	103	100	107	106	65	>1.91E-09	>1.91E-09	>1.91E-09	
Small Cell Lung Cancer																
DMS 114	0.203	0.462	0.478	0.493	0.464	0.466	0.428	106	112	101	102	87	>1.91E-09	>1.91E-09	>1.91E-09	
DMS 273	0.328	1.306	1.295	1.275	1.230	1.248	1.109	99	97	92	94	80	>1.91E-09	>1.91E-09	>1.91E-09	
Colon Cancer																
COLO 205	0.309	0.997	0.944	1.005	0.979	1.050	0.926	92	101	97	108	90	>1.91E-09	>1.91E-09	>1.91E-09	
DLD-1	0.199	0.790	0.776	0.794	0.813	0.826	0.743	96	101	104	106	92	>1.91E-09	>1.91E-09	>1.91E-09	
HCC-2998	0.314	0.866	0.752	0.894	0.906	0.919	0.812	79	105	107	109	90	>1.91E-09	>1.91E-09	>1.91E-09	
HCT-116	0.125	0.754	0.804	0.826	0.801	0.810	0.795	108	111	107	109	107	>1.91E-09	>1.91E-09	>1.91E-09	
HCT-15	0.269	1.413	1.367	1.383	1.396	1.480	1.092	96	97	99	106	72	>1.91E-09	>1.91E-09	>1.91E-09	
HT29	0.215	0.892	0.901	0.898	0.890	0.919	0.889	101	101	100	104	99	>1.91E-09	>1.91E-09	>1.91E-09	
KM12	0.501	1.751	1.809	1.766	1.793	1.793	1.627	105	103	103	103	90	>1.91E-09	>1.91E-09	>1.91E-09	
KM2012	0.249	0.785	0.800	0.842	0.813	0.808	0.755	103	111	105	104	94	>1.91E-09	>1.91E-09	>1.91E-09	
SW-620	0.230	1.117	1.095	1.162	0.927	0.677	0.729	98	105	79	73	56	>1.91E-09	>1.91E-09	>1.91E-09	
CNS Cancer																
SF-268	0.191	0.421	0.435	0.427	0.394	0.425	0.430	106	102	88	102	104	>1.91E-09	>1.91E-09	>1.91E-09	
SF-295	0.349	0.693	0.689	0.709	0.683	0.677	0.660	99	105	97	95	90	>1.91E-09	>1.91E-09	>1.91E-09	
SF-539	0.776	1.559	1.618	1.564	1.592	1.644	1.609	108	101	104	111	106	>1.91E-09	>1.91E-09	>1.91E-09	
SNB-19	0.465	1.222	1.176	1.109	1.099	1.006	1.065	94	85	84	71	79	>1.91E-09	>1.91E-09	>1.91E-09	
SNB-75	0.351	0.601	0.636	0.619	0.615	0.618	0.566	114	107	105	106	86	>1.91E-09	>1.91E-09	>1.91E-09	
SNB-78	0.607	0.942	0.938	0.931	0.905	0.933	0.907	99	97	89	97	90	>1.91E-09	>1.91E-09	>1.91E-09	
U251	0.242	0.807	0.729	0.799	0.816	0.844	0.847	86	99	102	107	107	>1.91E-09	>1.91E-09	>1.91E-09	
XF 498	0.475	0.585	0.592	0.587	0.601	0.569	0.610	107	102	115	86	123	>1.91E-09	>1.91E-09	>1.91E-09	
Melanoma																
LOX IMVI	0.264	0.876	0.878	0.900	0.921	0.942	0.847	100	104	107	111	95	>1.91E-09	>1.91E-09	>1.91E-09	
MALME-3M	0.716	1.142	1.135	1.237	1.210	1.295	1.170	98	122	116	136	107	>1.91E-09	>1.91E-09	>1.91E-09	
M14	0.263	0.812	0.825	0.810	0.811	0.808	0.689	102	100	100	99	77	>1.91E-09	>1.91E-09	>1.91E-09	
M19-MEL	0.328	0.815	0.819	0.824	0.865	0.840	0.682	101	102	110	105	73	>1.91E-09	>1.91E-09	>1.91E-09	
SK-MEL-2	0.677	1.334	1.324	1.308	1.305	1.275	1.218	98	96	95	91	82	>1.91E-09	>1.91E-09	>1.91E-09	
SK-MEL-28	0.550	1.034	1.014	1.020	0.994	1.002	0.995	96	97	92	93	92	>1.91E-09	>1.91E-09	>1.91E-09	
SK-MEL-5	0.593	1.605	1.508	1.554	1.581	1.710	1.357	90	95	98	110	75	>1.91E-09	>1.91E-09	>1.91E-09	
UACC-257	0.539	1.167	1.225	1.166	1.228	1.206	1.117	109	100	110	106	92	>1.91E-09	>1.91E-09	>1.91E-09	
UACC-62	0.507	1.043	0.982	1.073	1.038	1.040	1.020	89	106	99	99	96	>1.91E-09	>1.91E-09	>1.91E-09	
Ovarian Cancer																
IGROV1	0.485	0.995	0.948	0.928	0.993	0.975	0.679	91	87	100	96	77	>1.91E-09	>1.91E-09	>1.91E-09	
OVCAR-3	0.540	1.140	1.140	1.163	1.233	1.278	1.209	100	104	115	123	111	>1.91E-09	>1.91E-09	>1.91E-09	
OVCAR-4	0.319	0.639	0.673	0.667	0.666	0.634	0.629	110	109	108	98	97	>1.91E-09	>1.91E-09	>1.91E-09	
OVCAR-5	0.221	0.561	0.571	0.594	0.569	0.591	0.564	103	110	108	109	101	>1.91E-09	>1.91E-09	>1.91E-09	
OVCAR-8	0.410	0.981	0.997	1.044	1.058	1.080	1.163	103	111	113	117	132	>1.91E-09	>1.91E-09	>1.91E-09	
SK-OV-3	0.427	0.722	0.691	0.717	0.745	0.748	0.769	89	98	106	109	116	>1.91E-09	>1.91E-09	>1.91E-09	
Renal Cancer																
786-0	0.375	1.152	1.184	1.187	1.197	1.240	1.265	104	104	106	111	114	>1.91E-09	>1.91E-09	>1.91E-09	
A498	0.724	1.008	0.970	0.962	1.007	1.014	0.934	86	84	99	102	74	>1.91E-09	>1.91E-09	>1.91E-09	
ACHN	0.371	1.087	1.093	1.081	1.089	1.107	1.021	101	99	100	103	91	>1.91E-09	>1.91E-09	>1.91E-09	
CAKI-1	0.229	.	-0.013	-0.010	-0.013	-0.015	-0.010	
RXF-393	0.610	0.769	0.816	0.790	0.764	0.780	0.749	129	114	97	107	87	>1.91E-09	>1.91E-09	>1.91E-09	
RXF-631	0.516	1.010	1.017	1.054	1.014	1.062	1.108	102	109	101	111	120	>1.91E-09	>1.91E-09	>1.91E-09	
SN12C	0.371	0.800	0.807	0.801	0.750	0.769	0.815	102	100	88	97	103	>1.91E-09	>1.91E-09	>1.91E-09	
TK-10	0.681	1.347	1.378	1.317	1.335	1.349	1.444	105	96	98	100	115	>1.91E-09	>1.91E-09	>1.91E-09	
UO-31	0.618	0.966	1.004	1.011	1.001	0.995	0.922	111	113	110	108	87	>1.91E-09	>1.91E-09	>1.91E-09	

Mean Graphs

Report Date: December 2, 1991

Test Date: June 18, 1990



National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results

NSC: 631570 -W/1	Experiment ID: 9006NS33	Test Type: 8	Units: Molar
Report Date: December 2, 1991	Test Date: June 18, 1990	QNS:	MC:
COMI:	Stain Reagent: PROTEIN-51	SSPL: V27D	

Panel/Cell Line	Time Conc	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50	
			-7.4	-6.4	-5.4	-4.4	-3.4	-7.4	-6.4	-5.4	-4.4	-3.4				
Leukemia																
CCRF-CEM	0.362	1.871	1.937	1.471	0.597	0.562	0.367	90	85	16	.	1	1.27E-06	>3.63E-04	>3.63E-04	
HL-60(TB)	0.356	1.560	1.612	1.361	0.443	0.395	0.381	103	82	7	3	2	1.02E-06	>3.63E-04	>3.63E-04	
K-562	0.257	1.678	1.762	1.629	0.762	0.213	0.191	106	97	37	-17	-26	2.32E-06	1.65E-05	>3.63E-04	
MOLT-4	0.537	.	2.155	1.849	0.684	0.498	0.426	
RPMI-6226	0.613	.	2.499	2.396	1.554	0.503	0.483	
SR	0.496	2.024	2.076	2.059	0.648	0.482	0.370	104	102	23	-3	-26	1.75E-06	2.89E-05	>3.63E-04	
Non-Small Cell Lung Cancer																
A549/ATCC	0.305	1.547	1.600	1.600	0.832	0.587	0.092	104	104	42	23	-70	2.89E-06	6.73E-05	2.34E-04	
EKVX	0.594	1.000	0.924	0.969	0.913	0.846	0.045	81	92	79	62	-92	4.59E-05	9.67E-05	2.04E-04	
HOP-18	0.781	1.204	1.164	1.161	1.075	1.039	0.040	91	90	70	61	-95	4.52E-05	9.44E-05	1.97E-04	
HOP-62	1.067	2.043	2.005	1.977	1.753	1.078	0.036	96	93	70	1	-96	7.52E-06	3.93E-05	1.26E-04	
HOP-92	0.577	0.969	0.951	0.945	0.764	0.354	0.101	96	94	48	-39	-83	3.43E-06	1.37E-05	6.92E-05	
NCI-H226	0.816	1.180	1.191	1.177	0.953	0.841	0.696	103	99	38	7	-14	2.42E-06	7.96E-05	>3.63E-04	
NCI-H23	0.572	1.239	1.272	1.282	0.792	0.131	0.103	105	106	33	-77	-82	2.25E-06	7.63E-06	2.17E-05	
NCI-H322M	0.768	1.878	1.904	1.957	1.631	1.154	0.022	102	107	77	34	-97	1.61E-05	6.92E-05	1.67E-04	
NCI-H460	0.169	0.663	0.682	0.846	0.136	0.022	0.023	103	98	-20	-87	-86	9.76E-07	2.61E-06	1.08E-05	
NCI-H522	0.616	1.756	1.824	1.751	1.064	0.470	0.497	106	100	39	-24	-19	2.55E-06	1.61E-05	>3.63E-04	
LXFL 529	0.249	1.636	1.662	1.586	0.834	0.016	0.095	102	96	42	-94	-62	2.75E-06	7.83E-06	1.83E-05	
Small Cell Lung Cancer																
DMS 114	0.501	1.099	1.141	1.068	0.453	0.024	0.112	107	95	-10	-95	-76	1.03E-06	3.10E-06	1.14E-05	
DMS 273	0.562	.	2.493	2.513	1.335	0.414	0.162	
Colon Cancer																
COLO 205	0.279	1.439	1.461	1.511	0.484	0.052	0.072	102	106	16	-81	-74	1.65E-06	5.77E-06	1.85E-05	
DLD-1	0.216	1.088	1.122	1.041	0.437	0.099	0.043	104	95	25	-54	-80	1.68E-06	7.95E-06	3.37E-05	
HCC-2998	0.735	1.382	1.321	1.376	1.133	0.559	0.104	90	99	61	-24	-86	5.22E-06	2.01E-05	1.01E-04	
HCT-116	0.163	1.173	1.220	1.125	0.326	0.014	0.052	105	95	16	-91	-66	1.43E-06	5.41E-06	1.58E-05	
HT29	0.222	1.457	1.482	1.433	0.338	0.087	0.044	102	98	9	-61	-80	1.34E-06	5.21E-06	2.67E-05	
KM12	0.281	1.469	1.469	1.419	0.604	0.024	0.056	100	96	27	-91	-80	1.78E-06	6.49E-06	1.71E-05	
KM20L2	0.446	1.842	1.819	1.826	0.912	0.191	0.026	98	99	33	-57	-94	2.13E-06	6.91E-06	3.17E-05	
SW-620	0.148	1.030	1.039	0.937	0.317	0.039	0.061	101	89	19	-74	-59	1.40E-06	6.16E-06	2.13E-05	
CNS Cancer																
SF-268	0.586	1.527	1.529	1.492	1.181	0.664	0.664	100	96	63	8	8	6.67E-06	>3.63E-04	>3.63E-04	
SF-295	0.493	1.676	1.657	1.592	0.707	0.512	0.060	98	93	18	2	-88	1.43E-06	3.99E-05	1.45E-04	
SF-539	0.467	1.307	1.273	1.339	0.722	0.249	0.072	96	104	29	-49	-85	1.99E-06	8.99E-06	4.14E-05	
SNB-19	0.563	1.489	1.462	1.488	1.140	0.759	0.239	97	100	62	21	-58	7.66E-06	7.12E-05	3.07E-04	
SNB-75	0.545	0.966	0.947	0.954	0.547	0.466	0.037	96	97	0	-14	-93	1.18E-06	4.12E-06	1.06E-04	
SNB-76	0.578	1.263	1.308	1.230	0.877	0.332	0.507	104	92	42	-42	-12	2.70E-06	1.21E-05	>3.63E-04	
U251	0.214	1.043	1.048	1.020	0.473	0.018	0.046	101	97	31	-92	-79	1.99E-06	6.87E-06	1.76E-05	
XF 498	0.605	0.781	0.726	0.742	0.590	0.420	0.024	69	78	-2	-31	-96	8.46E-07	3.57E-06	7.56E-05	
Melanoma																
LOX IMVI	0.213	1.101	1.056	1.078	0.476	0.024	0.097	95	97	30	-89	-55	1.92E-06	6.61E-06	1.80E-05	
MALME-3M	0.556	1.118	1.131	1.070	0.754	0.296	0.169	102	91	35	-47	-70	2.09E-06	1.03E-05	5.35E-05	
M14	0.254	1.122	1.180	1.140	0.612	0.100	0.197	107	102	41	-61	-22	2.74E-06	9.70E-06	.	
M19-MEL	0.341	1.280	1.263	1.250	0.644	0.052	0.042	98	97	32	-85	-88	2.04E-06	7.23E-06	1.94E-05	
SK-MEL-28	0.478	1.348	1.373	1.378	0.895	0.088	0.137	103	103	46	-82	-71	3.50E-06	8.97E-06	2.16E-05	
SK-MEL-5	0.340	1.658	1.793	1.827	0.632	0.095	0.072	110	113	22	-72	-79	1.89E-06	6.56E-06	2.23E-05	
UACC-257	0.632	1.440	1.338	1.366	0.792	0.434	0.046	87	91	20	-31	-93	1.44E-06	9.33E-06	7.71E-05	
UACC-62	0.528	1.511	1.556	1.437	0.614	0.066	0.168	105	93	9	-88	-68	1.23E-06	4.72E-06	1.56E-05	
Ovarian Cancer																
IGROV1	0.532	1.711	1.689	1.682	1.240	0.352	0.159	98	98	60	-34	-70	4.90E-06	1.67E-05	1.06E-04	
OVCAR-3	0.626	1.392	1.427	1.446	0.764	0.325	0.010	105	107	18	-48	-98	1.68E-06	7.17E-06	4.18E-05	
OVCAR-4	0.316	0.652	0.627	0.680	0.524	0.104	0.046	92	108	62	-67	-85	4.74E-06	1.16E-05	2.82E-05	
OVCAR-8	0.354	1.605	1.691	1.623	1.095	0.250	0.425	107	101	59	-30	6	4.87E-06	.	>3.63E-04	
SK-OV-3	0.644	1.238	1.141	1.175	0.912	0.587	0.027	84	89	45	-9	-96	2.96E-06	2.62E-05	1.14E-04	
Renal Cancer																
766-0	0.518	1.866	1.854	1.875	1.463	0.106	0.058	99	101	70	-79	-89	5.22E-06	1.13E-05	2.44E-05	
A498	0.754	1.357	1.327	1.272	0.914	0.691	0.068	95	86	26	-8	-91	1.54E-06	2.20E-05	1.22E-04	
ACHN	0.641	1.837	1.857	1.863	1.287	0.286	0.035	102	102	54	-55	-95	4.16E-06	1.19E-05	3.42E-05	
CAKI-1	0.759	2.039	2.090	2.037	1.630	1.202	0.008	104	100	68	35	-99	1.32E-05	6.95E-05	1.65E-04	
RXF-393	0.751	1.208	1.245	1.163	0.886	0.191	0.151	108	90	29	-75	-80	1.76E-06	7.35E-06	2.22E-05	
RXF-631	0.384	1.638	1.580	1.523	0.858	0.204	0.167	95	91	38	-47	-57	2.25E-06	1.07E-05	8.00E-05	
SN12C	0.408	1.493	1.521	1.516	0.952	0.148	0.166	102	102	50	-64	-59	3.84E-06	1.05E-05	2.90E-05	
TK-10	0.709	1.341	1.355	1.464	1.251	0.549	0.007	102	120	86	-23	-99	8.20E-06	2.37E-05	8.74E-05	
UC-31	0.801	1.706	1.667	1.622	1.296	0.497	0.044	96	91	55	-38	-95	4.30E-06	1.49E-05	6.24E-05	

NCI Developmental Therapeutics Program Dose Response Matrix

NSC: 631570 -W/I

Exp. ID: 9006NS33

Test Date: June 18, 1990

Stain: PROTEIN-51

Report Date: December 2, 1991


SSPL: V27D

Log₁₀ Concentration (Molar)
PG (-4.4) -3.4 -4.4 -5.4 -6.4 -7.4


Panel/Cell Line

Log₁₀ TGI

TGI



Cell Line	Log ₁₀ TGI
Leukemia	
CCRF-CEM	> -3.42
HL-60(TB)	> -3.42
K-562	-4.73
MOLT-4	
RPMI-8226	
SR	-4.54
Non-Small Cell Lung Cancer	
AS49/ATCC	-4.17
EKVX	-4.01
HOP-18	-4.03
HOP-62	-4.41
HOP-92	-4.86
NCI-H226	-4.10
NCI-H23	-5.12
NCI-H322M	-4.16
NCI-H460	-5.58
NCI-H522	-4.79
LXFL 529	-5.11
• Small Cell Lung Cancer •	
DMS 114	-5.51
DMS 273	
Colon Cancer	
COLO 205	-5.24
DLD-1	-5.10
HCC-2998	-4.70
HCT-116	-5.27
HT29	-5.28
KM12	-5.19
KM20L2	-5.05
SW-620	-5.21
CNS Cancer	
SF-268	> -3.42
SF-295	-4.40
SF-539	-5.05
SNB-19	-4.15
SNB-75	-5.39
SNB-78	-4.92
U251	-5.16
XF 498	-5.45
Melanoma	
LOX IMVI	-5.17
MALME-3M	-4.99
M14	-5.01
M19-MEL	-5.14
SK-MEL-28	-5.05
SK-MEL-5	-5.18
UACC-257	-5.03
UACC-62	-5.33
Ovarian Cancer	
IGROV1	-4.78
OVCAR-3	-5.14
OVCAR-4	-4.94
OVCAR-8	
SK-OV-3	-4.58
Renal Cancer	
786-0	-4.95
A498	-4.66
ACHN	-4.92
CAKI-1	-4.16
RXF-393	-5.13
RXF-631	-4.97
SN12C	-4.98
TK-10	-4.63
UO-31	-4.83



PG > GI50
PG ≤ GI50
PG ≤ TGI
PG ≤ LC50










D_{GI50} = 39.0 (-5.4)
D_{TGI} = 96.0 (-5.4)
D_{LC50} = 58.0 (-4.4)
D_H = 100.0 (-4.4)

MG_MID TGI = -4.80
Delta = 0.78
Range = 2.17
MGD_H = 96.1

Dose Response Curves

Report Date: December 2, 1991

Test Date: June 18, 1990




Mean Graphs

Report Date: December 2, 1991

Test Date: April 16, 1990

Panel/Cell Line	Log ₁₀ G150	G150	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia	> -8.72		> -8.72		> -8.72	
HL-60(TB)	> -8.72		> -8.72		> -8.72	
K-562	> -8.72		> -8.72		> -8.72	
RFPMI-8226	> -8.72		> -8.72		> -8.72	
SR	> -8.72		> -8.72		> -8.72	
Non-Small Cell Lung Cancer						
AS-94(ATCC)	> -8.72		> -8.72		> -8.72	
EK VX	> -8.72		> -8.72		> -8.72	
HOP-18	> -8.72		> -8.72		> -8.72	
HOP-62	> -8.72		> -8.72		> -8.72	
HOP-92	> -8.72		> -8.72		> -8.72	
NCH-H23	> -8.72		> -8.72		> -8.72	
NCH-H322M	> -8.72		> -8.72		> -8.72	
NCH-H460	> -8.72		> -8.72		> -8.72	
NCH-H522	> -8.72		> -8.72		> -8.72	
LXFL-529	> -8.72		> -8.72		> -8.72	
Small Cell Lung Cancer						
DMS 114	> -8.72		> -8.72		> -8.72	
DMS 273	> -8.72		> -8.72		> -8.72	
Colon Cancer						
COLO 205	> -8.72		> -8.72		> -8.72	
DLD-1	> -8.72		> -8.72		> -8.72	
HCC-2998	> -8.72		> -8.72		> -8.72	
HCT-116	> -8.72		> -8.72		> -8.72	
HCT-15	> -8.72		> -8.72		> -8.72	
HT29	> -8.72		> -8.72		> -8.72	
KM12	> -8.72		> -8.72		> -8.72	
KM20L2	> -8.72		> -8.72		> -8.72	
SW-620	> -8.72		> -8.72		> -8.72	
CNS Cancer						
SF-268	> -8.72		> -8.72		> -8.72	
SF-295	> -8.72		> -8.72		> -8.72	
SF-539	> -8.72		> -8.72		> -8.72	
SNB-19	> -8.72		> -8.72		> -8.72	
SNB-75	> -8.72		> -8.72		> -8.72	
SNB-78	> -8.72		> -8.72		> -8.72	
U251	> -8.72		> -8.72		> -8.72	
XF-498	> -8.72		> -8.72		> -8.72	
Melanoma						
LOX IMVI	> -8.72		> -8.72		> -8.72	
MALME-3M	> -8.72		> -8.72		> -8.72	
M14	> -8.72		> -8.72		> -8.72	
M19-MEL	> -8.72		> -8.72		> -8.72	
SK-MEL-2	> -8.72		> -8.72		> -8.72	
SK-MEL-28	> -8.72		> -8.72		> -8.72	
SK-MEL-5	> -8.72		> -8.72		> -8.72	
UACC-257	> -8.72		> -8.72		> -8.72	
UACC-62	> -8.72		> -8.72		> -8.72	
Ovarian Cancer						
IGROV1	> -8.72		> -8.72		> -8.72	
OVCAR-3	> -8.72		> -8.72		> -8.72	
OVCAR-4	> -8.72		> -8.72		> -8.72	
OVCAR-5	> -8.72		> -8.72		> -8.72	
OVCAR-8	> -8.72		> -8.72		> -8.72	
SK-OV-3	> -8.72		> -8.72		> -8.72	
Renal Cancer						
786-0	> -8.72		> -8.72		> -8.72	
A-698	> -8.72		> -8.72		> -8.72	
ACHN	> -8.72		> -8.72		> -8.72	
CAKI-1	> -8.72		> -8.72		> -8.72	
RXF-393	> -8.72		> -8.72		> -8.72	
RXF-631	> -8.72		> -8.72		> -8.72	
SN12C	> -8.72		> -8.72		> -8.72	
TK-10	> -8.72		> -8.72		> -8.72	
UO-31	> -8.72		> -8.72		> -8.72	
MG_MID	-8.72		-8.72		-8.72	
Delta	0.00		0.00		0.00	
Range	0.00		0.00		0.00	



NCI Developmental Therapeutics Program Dose Response Matrix

NSC: 631570 -W/1

Exp. ID: 9004MD75

Test Date: April 16, 1990

Stain: PROTEIN-51

Report Date: December 2, 1991

SSPL: V27D



Log₁₀ Concentration (Molar)
PG (0.0) -8.7 -9.7 -10.7 -11.7 -12.7

Panel/Cell Line

Log₁₀ LC50

LC50

Leukemia
HL-60(TB) > -8.72
K-562 > -8.72
RPMI-8226 > -8.72
SR > -8.72
Non-Small Cell Lung Cancer
A549/ATCC > -8.72
EKVX > -8.72
HOP-18 > -8.72
HOP-62 > -8.72
HOP-92 > -8.72
NCI-H23 > -8.72
NCI-H322M > -8.72
NCI-H460 > -8.72
NCI-H522 > -8.72
LXFL 529 > -8.72
Small Cell Lung Cancer
DMS 114 > -8.72
DMS 273 > -8.72
Colon Cancer
COLO 205 > -8.72
DLD-1 > -8.72
HCC-2998 > -8.72
HCT-116 > -8.72
HCT-15 > -8.72
HT29 > -8.72
KM12 > -8.72
KM20L2 > -8.72
SW-620 > -8.72
CNS Cancer
SF-268 > -8.72
SF-295 > -8.72
SF-539 > -8.72
SNB-19 > -8.72
SNB-75 > -8.72
SNB-78 > -8.72
U251 > -8.72
XF 498 > -8.72
Melanoma
LOX IMVI > -8.72
MALME-3M > -8.72
M14 > -8.72
M19-MEL > -8.72
SK-MEL-2 > -8.72
SK-MEL-28 > -8.72
SK-MEL-5 > -8.72
UACC-257 > -8.72
UACC-62 > -8.72
Ovarian Cancer
IGROV1 > -8.72
OVCAR-3 > -8.72
OVCAR-4 > -8.72
OVCAR-5 > -8.72
OVCAR-8 > -8.72
SK-OV-3 > -8.72
Renal Cancer
786-0 > -8.72
A498 > -8.72
ACHN > -8.72
CAKI-1 > -8.72
RXF-393 > -8.72
RXF-631 > -8.72
SN12C > -8.72
TK-10 > -8.72
UO-31 > -8.72



PG > GI50
PG ≤ GI50
PG ≤ TGI
PG ≤ LC50

D_{GI50} = 0.0 (0.0)
D_{TGI} = 0.0 (0.0)
D_{LC50} = 0.0 (0.0)
D_H = 0.00 (0.0)

MG_MID LC50 = -8.72
Delta = 0.00
Range = 0.00
MGD_H = 0.00